Teva Ends Oncology, Women’s Health R&D Following Strategic Review
The company will focus its R&D resources on central nervous system disorders and respiratory disease, but will end investment in women’s health and oncology.
The company will focus its R&D resources on central nervous system disorders and respiratory disease, but will end investment in women’s health and oncology.